Immuno-oncology Service

Enhancing our patients' choice of therapeutic strategies

The rolling out of a progamme of immuno-oncology treatments is one of the priorities of the Department of oncology. The aim of such a programme is to offer access to innovative therapies to those patients who have not responded to standard treatments, namely within the context of enrolment in one of its clinical trials.

Yielding new immunity equilibriums against cancer

The Immuno-oncology service is dedicated to early phase clinical research in cancer immunotherapies. 

Available treatments

Its vocation is to offer a large portfolio of clinical trials centred on the development of innovative therapies which harness the intrinsic characteristics of the immune system. As such, our immuno-oncology patient care includes:

  • local clinical trials, developed on the basis of preclinical results obtained at the University Hospital of Lausanne and the Ludwig Institute for Cancer Research Lausanne
  • clinical trials sponsored by the pharmaceuticals sector, designed to evaluate the safety and toxicity of new immuno-oncology substances

The cancer-immunity cycle in our sights

A programme of adoptive cellular therapy, based on TIL (tumour-infiltrating lymphocyte) cells, allows us to propose treatments which rationally target the various stages of the cancer-immunity cycle. This is achieved by promoting immunogenicity, the presentation of tumoral antigens, the reactivation and potentiation of T lymphocyte cells, and supporting their entry into the tumour environment. 

The therapies draw on a broad spectrum of therapeutic/drug classes being developed, including monoclonal antibodies with inhibitory or agonist activities, modified cytokines or immunocytokines and oncolytic viruses. The intent is to garner a new, lasting and efficient anti-tumour immune equilibrium.

Cellular engineering of tomorrow

In the future, the portfolio will be enriched by other trials, currently under development, based on genetically modified T lymphocyte cells, applicable to hematologic malignancies and solid tumours alike. 

 Last updated on 17/10/2019 at 15:00